95 related articles for article (PubMed ID: 11082720)
21. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
Watanabe M; Aoki Y; Tomita M; Sato T; Takaki Y; Kato N; Kikuchi M; Kase H; Tanaka K
Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
[TBL] [Abstract][Full Text] [Related]
22. Comparative clinical pharmacology of cisplatin and carboplatin.
Murry DJ
Pharmacotherapy; 1997; 17(5 Pt 2):140S-145S. PubMed ID: 9322881
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line--a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia.
Guminski AD; Harnett PR; deFazio A
Cancer Chemother Pharmacol; 2001 Sep; 48(3):229-34. PubMed ID: 11592345
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Ma J; Verweij J; Planting AS; Kolker HJ; Loos WJ; de Boer-Dennert M; van der Burg ME; Stoter G; Schellens JH
Cancer Chemother Pharmacol; 1996; 37(4):382-4. PubMed ID: 8548886
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotective interactions in rats between paclitaxel and cisplatin.
McKeage MJ; Haddad GG; Ding L; Galettis P; Screnci D; Zhuang L; Baguley BC
Oncol Res; 1999; 11(6):287-93. PubMed ID: 10691031
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
Xu L; Zuch CL; Lin YS; Modi NB; Lum BL
Cancer Chemother Pharmacol; 2008 Apr; 61(4):607-14. PubMed ID: 17549476
[TBL] [Abstract][Full Text] [Related]
27. [Carboplatin in pediatrics].
Doz F
Bull Cancer; 2000 Aug; 87 Spec No():25-9. PubMed ID: 11082719
[TBL] [Abstract][Full Text] [Related]
28. Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
Clouse T; Geisler JP; Manahan KJ; Gudenkauf TJ; Linnemeier G; Wiemann MC
Gynecol Oncol; 2004 Oct; 95(1):270-1. PubMed ID: 15385146
[No Abstract] [Full Text] [Related]
29. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review.
Bin P; Boddy AV; English MW; Pearson AD; Price L; Tilby MJ; Newell DR
Anticancer Res; 1994; 14(6A):2279-83. PubMed ID: 7825959
[TBL] [Abstract][Full Text] [Related]
30. In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
de Graaff M; Maliepaard M; Pluim D; Floot BJ; Slaper-Cortenbach IC; Schellens JH
Anticancer Drugs; 1999 Feb; 10(2):213-8. PubMed ID: 10211552
[TBL] [Abstract][Full Text] [Related]
31. Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Vaishampayan U; Parchment RE; Jasti BR; Hussain M
Urology; 1999 Dec; 54(6A Suppl):22-9. PubMed ID: 10606281
[TBL] [Abstract][Full Text] [Related]
32. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A
Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335
[TBL] [Abstract][Full Text] [Related]
33. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
Vigano L; Locatelli A; Grasselli G; Gianni L
Invest New Drugs; 2001 May; 19(2):179-96. PubMed ID: 11392452
[TBL] [Abstract][Full Text] [Related]
34. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
Thomas HD; Porter DJ; Bartelink I; Nobbs JR; Cole M; Elliott S; Newell DR; Calvert AH; Highley M; Boddy AV
Br J Clin Pharmacol; 2002 Jan; 53(1):83-91. PubMed ID: 11849199
[TBL] [Abstract][Full Text] [Related]
35. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin.
Boyle FM; Beatson C; Monk R; Grant SL; Kurek JB
Cancer Chemother Pharmacol; 2001 Dec; 48(6):429-34. PubMed ID: 11800022
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.
Hammann F; Gotta V; Conen K; Medinger M; Cesana P; Rochlitz C; Taegtmeyer AB
Br J Clin Pharmacol; 2017 Apr; 83(4):927-930. PubMed ID: 27868228
[TBL] [Abstract][Full Text] [Related]
37. [Platinum derivatives in pediatric oncology].
Doz F; Pinkerton R; Pacquement H; Michon J; Quintana E; Bastian G; Chazard M; Pellae-Cosset B; Zucker JM
Arch Fr Pediatr; 1993 Apr; 50(4):353-9. PubMed ID: 8379826
[No Abstract] [Full Text] [Related]
38. DNA-based drug interactions of cisplatin.
Crul M; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Treat Rev; 2002 Dec; 28(6):291-303. PubMed ID: 12470980
[TBL] [Abstract][Full Text] [Related]
39. In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve.
Kobayashi K; Kudoh S; Takemoto T; Hino M; Hayashihara K; Nakahiro K; Ando M; Niitani H
J Cancer Res Clin Oncol; 1995; 121(12):715-20. PubMed ID: 7499442
[TBL] [Abstract][Full Text] [Related]
40. A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.
Mendes MS; Hatley O; Gill KL; Yeo KR; Ke AB
Eur J Pharm Sci; 2020 Jul; 150():105355. PubMed ID: 32438273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
